Prognostic variables in node-negative and node-positive breast cancer

Portada
Giampietro Gasparini
Springer Science & Business Media, 28 feb 1999 - 428 páginas
During the last decade, important advancements on the understanding of the molecular mechanisms involved in tumorigenesis and progression of breast cancer have been made, particularly regarding the mechanisms of control of the cell cycle, apoptosis, metastasis, and angiogenesis. Translation of basic research to the clinical setting by the identification of assessable markers associated with the above biological mechanisms has permitted verification of the clinical significance of several prognostic indicators and has highlighted the heterogeneous nature of invasive breast cancer.Reprinted from Breast Cancer Research And Treatment, this text contains original papers, overviews, and position papers on the methodological aspects and the clinical significance of the more interesting prognostic and predictive indicators. Ultimately, the determination of biological prognostic and predictive markers with easily applicable, reproducible, and standardizable assays is an integral part of future research aimed to improve the management of patients operated for breast cancer in the years to come. Novel therapeutic strategies based not only on chemotherapy or hormone therapy, but directed at interfering with the molecular targets involved in tumor progression and metastasis, warrant clinical testing and are a major challenge to enhance the potential cure of breast cancer.
 

Páginas seleccionadas

Índice

Prognostic variables in nodenegative and nodepositive breast cancer Introduction
1
Routinely available indicators of prognosis in breast cancer
3
Prognostic factors for patients with breast cancers 1cm and smaller
17
Steroid hormone receptors in breast cancer management
35
Sphase fraction combined with other patient and tumor characteristics for the prognosis of nodenegative estrogenreceptorpositive breast cancer
47
Sphase fraction and breast cancer a decade of experience
63
Prognostic and predictive value of thymidine labelling index in breast cancer
75
Cyclin Dl in breast cancer
91
The 67 kDa laminin receptor as a prognostic factor in human cancer
225
Assessment of intratumoral vascularization angiogenesis in breast cancer prognosis
235
Clinical significance of angiogenic factors in breast cancer
247
Insulinlike growth factors in human breast cancer
263
Molecular prognostic markers in breast cancer
273
Prognostic significance of micrometastatic bone marrow involvement
289
Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis1
305
cancer
315

Cyclins and breast cancer
107
Prognostic implications of expression of the cell cycle inhibitor protein p27Klpl
119
new ligands and receptors and their role in breast cancer
133
cerbB2 expression predicts tamoxifen efficacy in breast cancer patients
145
HER2neu as a predictive marker of response to breast cancer therapy
155
Prognostic and predictive value of p53 and p21 in breast cancer
169
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
187
Metalloproteinases and tissue inhibitors of metalloproteinases
201
Matrix metalloproteinase inhibitors
213
Accepted utilities and novel prospects
327
The relationship between prognostic and predictive factors in the management of breast cancer
349
Methodological challenges in the evaluation of prognostic factors in breast cancer
377
When is statistically significant clinically useful?
393
Prognostic variables in nodenegative and nodepositive breast cancer editorial
409
Author index page numbers at the bottom of the page
421
Subject index page numbers at the bottom of the pages
Página de créditos

Otras ediciones - Ver todo

Términos y frases comunes

Referencias a este libro

Atlas of Breast Cancer
Daniel F. Hayes
Vista de fragmentos - 2000

Información bibliográfica